S&P 500   3,315.57 (+1.05%)
DOW   27,288.18 (+0.52%)
QQQ   272.48 (+1.86%)
AAPL   111.81 (+1.57%)
MSFT   207.42 (+2.41%)
FB   254.75 (+2.66%)
GOOGL   1,459.82 (+2.08%)
AMZN   3,128.99 (+5.69%)
NVDA   505.51 (+0.96%)
TSLA   424.23 (-5.60%)
BABA   275.29 (+0.54%)
CGC   16.04 (+1.91%)
GE   6.25 (-1.57%)
MU   49.70 (+1.12%)
AMD   77.70 (-0.31%)
T   28.51 (-0.42%)
F   6.78 (-1.31%)
ACB   7.32 (+15.82%)
GILD   63.40 (-1.26%)
NFLX   491.17 (+0.78%)
DIS   127.21 (+1.44%)
BAC   23.94 (-2.17%)
BA   156.80 (+0.29%)
S&P 500   3,315.57 (+1.05%)
DOW   27,288.18 (+0.52%)
QQQ   272.48 (+1.86%)
AAPL   111.81 (+1.57%)
MSFT   207.42 (+2.41%)
FB   254.75 (+2.66%)
GOOGL   1,459.82 (+2.08%)
AMZN   3,128.99 (+5.69%)
NVDA   505.51 (+0.96%)
TSLA   424.23 (-5.60%)
BABA   275.29 (+0.54%)
CGC   16.04 (+1.91%)
GE   6.25 (-1.57%)
MU   49.70 (+1.12%)
AMD   77.70 (-0.31%)
T   28.51 (-0.42%)
F   6.78 (-1.31%)
ACB   7.32 (+15.82%)
GILD   63.40 (-1.26%)
NFLX   491.17 (+0.78%)
DIS   127.21 (+1.44%)
BAC   23.94 (-2.17%)
BA   156.80 (+0.29%)
S&P 500   3,315.57 (+1.05%)
DOW   27,288.18 (+0.52%)
QQQ   272.48 (+1.86%)
AAPL   111.81 (+1.57%)
MSFT   207.42 (+2.41%)
FB   254.75 (+2.66%)
GOOGL   1,459.82 (+2.08%)
AMZN   3,128.99 (+5.69%)
NVDA   505.51 (+0.96%)
TSLA   424.23 (-5.60%)
BABA   275.29 (+0.54%)
CGC   16.04 (+1.91%)
GE   6.25 (-1.57%)
MU   49.70 (+1.12%)
AMD   77.70 (-0.31%)
T   28.51 (-0.42%)
F   6.78 (-1.31%)
ACB   7.32 (+15.82%)
GILD   63.40 (-1.26%)
NFLX   491.17 (+0.78%)
DIS   127.21 (+1.44%)
BAC   23.94 (-2.17%)
BA   156.80 (+0.29%)
S&P 500   3,315.57 (+1.05%)
DOW   27,288.18 (+0.52%)
QQQ   272.48 (+1.86%)
AAPL   111.81 (+1.57%)
MSFT   207.42 (+2.41%)
FB   254.75 (+2.66%)
GOOGL   1,459.82 (+2.08%)
AMZN   3,128.99 (+5.69%)
NVDA   505.51 (+0.96%)
TSLA   424.23 (-5.60%)
BABA   275.29 (+0.54%)
CGC   16.04 (+1.91%)
GE   6.25 (-1.57%)
MU   49.70 (+1.12%)
AMD   77.70 (-0.31%)
T   28.51 (-0.42%)
F   6.78 (-1.31%)
ACB   7.32 (+15.82%)
GILD   63.40 (-1.26%)
NFLX   491.17 (+0.78%)
DIS   127.21 (+1.44%)
BAC   23.94 (-2.17%)
BA   156.80 (+0.29%)
Log in
OTCMKTS:DSNKY

DAIICHI SANKYO/S Stock Forecast, Price & News

$90.71
+0.16 (+0.17 %)
(As of 09/22/2020 01:59 PM ET)
Add
Compare
Today's Range
$90.51
Now: $90.71
$90.71
50-Day Range
$86.35
MA: $90.02
$96.00
52-Week Range
$48.34
Now: $90.71
$96.30
Volume3,909 shs
Average Volume11,540 shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Daiichi Sankyo Company, Limited researches and develops, manufactures, imports, and markets pharmaceutical products worldwide. The company offers prasugrel, an antiplatelet agent; denosumab for osteoporosis and bone compilations; teneligliptin for type 2 diabetes mellitus treatment; edoxaban, an anticoagulant; esomeprazole for ulcer treatment; memantine and donepezil for treating Alzheimer's disease; laninamivir for anti-influenza treatment; and silodosin for treating dysuria. It also provides olmesartan and Telmisartan antihypertensive agents; levofloxacin, an antibacterial agent; pravastatin and Rosuvastatin antihyperlipidemic agents; iohexol to enhance the visibility of diagnostic X-ray imaging; loxoprofen, an anti-inflammatory analgesic; and naloxegol for opioid-induced constipation treatment. In addition, the company offers colesevelam for treating hypercholesterolemia and type 2 diabetes mellitus treatment; and ferric carboxymaltose and iron sucrose injections for treating anemia. Further, it provides Lulu, a cold remedy; Loxonin S, an anti-inflammatory analgesic; Transino for treating melisma/alleviating spots, freckles, and pigmentation; Minon, a moisturizing cleanser; and Clean Dental, an oral care product. Additionally, the company offers Influenza HA Vaccine; Rotarix Oral Liquid, a vaccine for prevention of rotavirus; ActHIB, a haemophilus influenzae type b vaccine; Live Attenuated Measles-Rubella Combined Vaccine; and Squarekids, a vaccine for the prevention of pertussis, diphtheria, tetanus, and poliomyelitis. It also offers pharmaceuticals and drugs for animals, cosmetics, medical equipment, food products, drinking water, active pharmaceutical ingredients, and intermediates. It has collaboration agreements with Roche for the development of a HER2 diagnostic test; Sarah Cannon Research Institute to develop novel cancer therapies; and Integral Molecular, Inc. The company was founded in 1899 and is headquartered in Tokyo, Japan.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.1Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.42 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceuticals: Other
Sub-IndustryN/A
Current SymbolOTCMKTS:DSNKY
CUSIPN/A
CIKN/A
Phone(136) 225-1111

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

Employees14,446
Next Earnings DateN/A
OptionableNot Optionable
$90.71
+0.16 (+0.17 %)
(As of 09/22/2020 01:59 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive DSNKY News and Ratings via Email

Sign-up to receive the latest news and ratings for DSNKY and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











DAIICHI SANKYO/S (OTCMKTS:DSNKY) Frequently Asked Questions

How has DAIICHI SANKYO/S's stock price been impacted by COVID-19?

DAIICHI SANKYO/S's stock was trading at $57.75 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, DSNKY stock has increased by 57.1% and is now trading at $90.7050.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of DAIICHI SANKYO/S?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for DAIICHI SANKYO/S in the last year. There are currently 1 hold rating for the stock, resulting in a consensus recommendation of "Hold."
View analyst ratings for DAIICHI SANKYO/S
.

What guidance has DAIICHI SANKYO/S issued on next quarter's earnings?

DAIICHI SANKYO/S issued an update on its FY 2021 Pre-Market earnings guidance on Friday, July, 31st. The company provided earnings per share (EPS) guidance of 0.80-0.80 for the period. The company issued revenue guidance of $9.021-9.021 billion.

Are investors shorting DAIICHI SANKYO/S?

DAIICHI SANKYO/S saw a increase in short interest in the month of August. As of August 31st, there was short interest totaling 13,000 shares, an increase of 17.1% from the August 15th total of 11,100 shares. Based on an average daily volume of 10,500 shares, the short-interest ratio is currently 1.2 days.
View DAIICHI SANKYO/S's Short Interest
.

Who are some of DAIICHI SANKYO/S's key competitors?

Who are DAIICHI SANKYO/S's key executives?

DAIICHI SANKYO/S's management team includes the following people:
  • Mr. Joji Nakayama, Chairman & Global CEO (Age 69)
  • Mr. Sunao Manabe, Pres, COO & Representative Director (Age 65)
  • Mr. Toshiaki Sai, CFO, Exec. VP, Head of Corp. Strategy & Management Division and Representative Director
  • Mr. Junichi Onuma, Sr. Director of IR Group
  • Mr. Yoshihiro Aoyagi, Head of Corp. Affairs Division, Exec. Officer & Gen. Counsel

What is DAIICHI SANKYO/S's stock symbol?

DAIICHI SANKYO/S trades on the OTCMKTS under the ticker symbol "DSNKY."

How do I buy shares of DAIICHI SANKYO/S?

Shares of DSNKY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is DAIICHI SANKYO/S's stock price today?

One share of DSNKY stock can currently be purchased for approximately $90.71.

What is DAIICHI SANKYO/S's official website?

The official website for DAIICHI SANKYO/S is www.daiichisankyo.com.

How can I contact DAIICHI SANKYO/S?

The company can be reached via phone at (136) 225-1111.

This page was last updated on 9/22/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.